Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary…
Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including…
Read More...
Read More...